Novel BTK Inhibitors: Effects on Adaptive and Innate Immunity in Multiple Sclerosis


I. Why We Need New Approaches to Treating MS – Fred D. Lublin, MD

II. The Science of BTK Inhibitors: Adaptive and Innate Immunity
– Benjamin M. Greenberg, MD, MHS

III. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel BTK Inhibitors – Mark S. Freedman, MD

IV. Faculty Panel Discussion: Treatment Strategies for the Application of BTK-Inhibitor Therapeutics to Optimize MS Patient Outcomes – Fred D. Lublin & Faculty

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 Credits TM. Participants should claim only the credit commensurate with the extent of their participation in the activity.

For all CME inquiries or special needs, please contact [email protected] or 610-687-3300.

This activity has been supported by an independent educational grant from Sanofi Genzyme.

*This symposium is neither sponsored nor endorsed by the Consortium of Multiple Sclerosis Centers.

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts